Long-lived t cells, pharmaceutical composition, and method of use
JPWO2025089255A1Undetermined Publication Date: 2025-05-01
View PDF 0 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Filing Date
- 2024-10-22
- Publication Date
- 2025-05-01
AI Technical Summary
Technical Problem
Current CAR-T cell therapies face challenges with T cell aging and exhaustion, leading to reduced viability and cytotoxicity over time.
Method used
The development of T cells with reduced or excluded expression and/or function of the PRDM1 and RCOR1 genes, combined with increased or activated expression of the c-Jun gene, to enhance long-term viability and fatigue resistance.
Benefits of technology
This approach results in T cells with sustained cytotoxicity and improved therapeutic efficacy, maintaining memory phenotype and cytokine production while reducing exhaustion markers.
✦ Generated by Eureka AI based on patent content.
Abstract
The present invention provides T cells that express a recombinant receptor and satisfying conditions (I) and (II). (I) T cells having reduced or eliminated expression and / or function of the PRDM1 gene (II) T cells having reduced or eliminated expression and / or function of the RCOR1 gene, and / or increased or activated expression of the c-Jun gene
Need to check novelty before this filing date? Find Prior Art